| |
Article Title |
Author(s) |
Type (Status) |
Available Online |
|
Retraction notice to “Curcumin suppresses constitutive activation of AP-1 by downregulation of JunD protein in HTLV-1-infected T-cell lines” [Leuk. Res. 30 (2006) 313–321]
DOI: 10.1016/j.leukres.2012.01.014
This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy).
|
Mariko Tomita,
Hirochika Kawakami,
Jun-nosuke Uchihara,
Taeko Okudaira,
Masato Masuda,
Nobuyuki Takasu,
Takehiro Matsuda,
Takao Ohta,
Yuetsu Tanaka,
Naoki Mori
et al.
|
Erratum
(In Press Corrected Proof)
|
22 February 2012 |
|
Vitamin D protects acute lymphoblastic leukemia cells from dexamethasone
DOI: 10.1016/j.leukres.2012.01.011
Abstract: Vitamin D deficiency has been linked with increased cancer risk, and vitamin D has been shown to be cytotoxic to some cancer cells in vitro. In the present study we evaluated whether vitamin...
|
Reuben Antony,
Xia Sheng,
Ehsan A. Ehsanipour,
Emily Ng,
Rocky Pramanik,
Lars Klemm,
Brian Ichihara,
Steven D. Mittelman
et al.
|
Short communication
(In Press Corrected Proof)
|
20 February 2012 |
|
Post-transcriptional modulation of C/EBPα prompts monocytic differentiation and apoptosis in acute myelomonocytic leukaemia cells
DOI: 10.1016/j.leukres.2012.01.009
Abstract: CCAAT/enhancer binding protein alpha (C/EBPα) induction induces monocytic differentiation even in acute myeloid leukaemia (AML). In this study, the induction/activation of C/EBPα in myelomon...
|
Hideki Yoshida,
Toshihiko Imamura,
Atsushi Fujiki,
Yoshifumi Hirashima,
Mitsuru Miyachi,
Takeshi Inukai,
Hajime Hosoi
et al.
|
Full-length article
(In Press Corrected Proof)
|
20 February 2012 |
|
Thrombomodulin-induced differentiation of acute myelomonocytic leukemia cells via JNK signaling
DOI: 10.1016/j.leukres.2012.01.019
Abstract: We found recombinant human soluble thrombomodulin (rTM) induced growth arrest and differentiation of THP-1 cells by activating JNK/c-Jun signaling. Further activation of JNK by 1,25-(OH)2D3 ...
|
Jing Yang,
Takayuki Ikezoe,
Chie Nishioka,
Goichi Honda,
Akihito Yokoyama
et al.
|
Full-length article
(In Press Corrected Proof)
|
20 February 2012 |
|
Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro
DOI: 10.1016/j.leukres.2012.01.020
Abstract: Some oncolytic viruses, such as myxoma virus (MYXV), can selectively target malignant hematopoietic cells, while sparing normal hematopoietic cells. This capacity for discrimination creates ...
|
Gerard J. Madlambayan,
Eric Bartee,
Manbok Kim,
Masmudur M. Rahman,
Amy Meacham,
Edward W. Scott,
Grant McFadden,
Christopher R. Cogle
et al.
|
Full-length article
(In Press Corrected Proof)
|
20 February 2012 |
|
Development of a multiplex PCR assay for the detection of genomic copy number changes in myelodysplastic syndromes
DOI: 10.1016/j.leukres.2012.01.007
Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematologic malignancies characterized by ineffective hematopoiesis . The International Prognostic Scoring System (IPSS) introduces c...
|
Aspasia Stamatoullas,
Agathe Waultier,
Fabrice Jardin,
Marie Paule Callat,
Françoise Parmentier,
Celine Burgot,
Dominique Penther,
Hervé Tilly,
Christian Bastard
et al.
|
Correspondence
(In Press Corrected Proof)
|
17 February 2012 |
|
Establishment and characterization of a new human acute myelomonocytic leukemia cell line JIH-3
DOI: 10.1016/j.leukres.2012.01.012
Abstract: Here, a new acute myelomonocytic leukemia (AMML) cell line, JIH-3, is reported, and its biological characteristics are described. JIH-3 cells were maintained without any cytokines for 27 mon...
|
Jinlan Pan,
Yongquan Xue,
Suning Chen,
Huiying Qiu,
Chunxiao Wu,
Hui Jiang,
Qian Wang,
Jun Zhang,
Suxiao Bai,
Yafang Wu,
Yong Wang,
Juan Shen
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 February 2012 |
|
Book review
DOI: 10.1016/j.leukres.2012.01.016
This multiauthored extensive review of molecular hematopathology is the first volume in a series on Molecular and Translational Medicine edited by William Coleman and Gregory Tsongalis. The book is an...
|
Paul G. Rothberg
|
Book review
(In Press Corrected Proof)
|
15 February 2012 |
|
RBC-transfusion guidelines update
DOI: 10.1016/j.leukres.2012.01.023
Results of our RAND Delphi consensus-panel report: What are RBC-transfusion-dependence and -independence? (Leuk Res 2011;35:8–11) have been well-received and widely adopted in clinical trials of anemi...
|
R.P. Gale,
G. Barosi,
T. Barbui,
F. Cervantes,
K. Dohner,
B. Dupriez,
V. Gupta,
C. Harrison,
R. Hoffman,
J.J. Kiladjian,
R. Mesa,
M.F. Mc Mullin,
F. Passamonti,
V. Ribrag,
G. Roboz,
G. Saglio,
A. Vannucchi,
S. Verstovsek
et al.
|
Correspondence
(In Press Corrected Proof)
|
15 February 2012 |
|
Transfusions at home in patients with myelodysplastic syndromes
DOI: 10.1016/j.leukres.2012.01.010
Abstract: We report descriptive data of a home care (HC) program, throughout a 5-years period (2006–2010), focusing on the reliability and the safety of transfusions at home in 211 patients affected b...
|
Pasquale Niscola,
Andrea Tendas,
Marco Giovannini,
Luca Cupelli,
Malgorzata Monika Trawinska,
Massimiliano Palombi,
Laura Scaramucci,
Gregorio Antonio Brunetti,
Alessio Perrotti,
Benedetta Neri,
Fabio Efficace,
Claudio Cartoni,
Paolo de Fabritiis,
Franco Mandelli
et al.
|
Full-length article
(In Press Corrected Proof)
|
15 February 2012 |
|
High expression of hematopoietic cell specific Lyn substrate-1 (HS1) predicts poor survival of B-cell chronic lymphocytic leukemia patients
DOI: 10.1016/j.leukres.2012.01.017
Abstract: B-cell chronic lymphocytic leukemia (B-CLL) is the most common leukemia in adults in western countries. HS1 protein regulates leukemic cell migration and homing, and can indirectly promote d...
|
Aleksandra Butrym,
Miroslaw Majewski,
Justyna Dzietczenia,
Kazimierz Kuliczkowski,
Grzegorz Mazur
et al.
|
Full-length article
(In Press Corrected Proof)
|
14 February 2012 |
|
The clinical impact of DNA methylation frequencies of JAK2 negative regulators in patients with essential Thrombocythemia
DOI: 10.1016/j.leukres.2012.01.008
Abstract: Suppressors of cytokine signalling (SOCS) and protein tyrosine phosphatase (PTPN) proteins are negative regulators of Janus Kinase 2 (JAK2). They are thought to be involved in the molecular ...
|
Mathilde Födermayr,
Otto Zach,
Maria Huber,
Sigrid Machherndl-Spandl,
Soraya Wölfl,
Hans-Christian Bösmüller,
Sonja Hasenschwandtner,
Sonja Burgstaller,
Otto Krieger,
Dieter Lutz,
Ansgar Weltermann,
Hanns Hauser
et al.
|
Short communication
(In Press Corrected Proof)
|
13 February 2012 |
|
The Smac mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac
DOI: 10.1016/j.leukres.2011.12.024
Abstract: The inhibitors of apoptosis (IAP) are important regulators of apoptosis. However, little is known about the capacity of Smac mimetics (IAP inhibitor) to overcome virally associated-lymphoma'...
|
Sampath Ramachandiran,
Joan Cain,
Albert Liao,
Yanjuan He,
Xiangxue Guo,
Lawrence H. Boise,
Haian Fu,
Lee Ratner,
Hanna Jean Khoury,
Leon Bernal-Mizrachi
et al.
|
Full-length article
(In Press Corrected Proof)
|
13 February 2012 |
|
Neutropenia at baseline could indicate poor prognosis in low/intermediate risk myelodysplastic syndrome patients
DOI: 10.1016/j.leukres.2012.01.003
We read with interest the article by Cordoba et al. , which reported that the degree of neutropenia at baseline has a prognostic impact in low risk myelodysplastic syndromes (MDS). They referred that ...
|
Massimo Breccia,
Giuseppina Loglisci,
Adriano Salaroli,
Paola Finsinger,
Alessandra Serrao,
Luigi Petrucci,
Giuliana Alimena
et al.
|
Discussion
(In Press Corrected Proof)
|
10 February 2012 |
|
A novel three-way variant t(4;17;5)(p16;q23;q31) in a case of secondary plasma cell leukemia
DOI: 10.1016/j.leukres.2012.01.004
Plasma cell leukemia (PCL) is a rare and aggressive variant of plasma cell myeloma that is classically divided into primary and secondary subtypes. The incidence of sPCL (40% of all PCL cases) which ...
|
Yoonjung Kim,
Juwon Kim,
Seo-Jin Park,
Jong Rak Choi,
Kyung-A Lee,
Yu Ri Kim
et al.
|
Correspondence
(In Press Corrected Proof)
|
10 February 2012 |
|
AZA-ESA combo: A new standard for higher risk MDS?
DOI: 10.1016/j.leukres.2012.01.002
The cloning of the erythropoietin (EPO) gene, more than two decades ago , followed by the production of recombinant human erythropoietin (rHuEPO), allowed millions of patients with anemia to benefit f...
|
Moshe Mittelman
|
Editorial
(In Press Corrected Proof)
|
10 February 2012 |
|
Are low-intensity induction strategies better for older patients with acute myeloid leukemia?
DOI: 10.1016/j.leukres.2011.12.019
Abstract: This study compares outcomes of low-intensity versus standard-intensity induction strategies for older patients with acute myeloid leukemia at the Weill Cornell Leukemia Program. From 1999 t...
|
Gail J. Roboz,
Usama Wissa,
Ellen K. Ritchie,
Usama Gergis,
Sebastian Mayer,
Joseph M. Scandura,
Paul J. Christos,
Eric J. Feldman
et al.
|
Full-length article
(In Press Corrected Proof)
|
10 February 2012 |
|
Sequential array comparative genomic hybridization analysis identifies copy number changes during blastic transformation of chronic myeloid leukemia
DOI: 10.1016/j.leukres.2011.12.021
Abstract: The present study was performed to provide direct evidence on copy number changes during progression from chronic phase (CP) to blastic phase (BP) in chronic myeloid leukemia (CML) through a...
|
Seung-Tae Lee,
Yongick Ji,
Hee-Jin Kim,
Chang-Seok Ki,
Chul Won Jung,
Jong-Won Kim,
Sun-Hee Kim
et al.
|
Full-length article
(In Press Corrected Proof)
|
10 February 2012 |
|
A tribute to Professor Terence “Terry” John Hamblin
DOI: 10.1016/j.leukres.2012.01.013
|
John M. Bennett,
Daniel Catovsky,
David Bowen
|
Personal report
(In Press Corrected Proof)
|
06 February 2012 |
|
Abl-interactor 2 (ABI2): A novel MLL translocation partner in acute myeloid leukemia
DOI: 10.1016/j.leukres.2012.01.005
Mixed-Lineage Leukemia (MLL)-rearrangements are frequently involved in both adult and childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). In childhood they are especially fr...
|
Eva A. Coenen,
C. Michel Zwaan,
Claus Meyer,
Rolf Marschalek,
Ursula Creutzig,
Rob Pieters,
Jutta Bradtke,
Marry M. van den Heuvel-Eibrink
et al.
|
Correspondence
(In Press Corrected Proof)
|
03 February 2012 |
|
The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes
DOI: 10.1016/j.leukres.2012.01.006
Abstract: Most patients with myelodysplastic syndromes (MDS) require transfusions due to chronic anemia. Apart from the acute risks associated with transfusions, chronic anemia and red blood cell (RBC...
|
Uwe Platzbecker,
Lorenz C. Hofbauer,
Gerhard Ehninger,
Kristina Hölig
|
Review article
(In Press Corrected Proof)
|
02 February 2012 |
|
Differential diagnosis of paediatric bone pain: Acute lymphoblastic leukemia
DOI: 10.1016/j.leukres.2012.01.001
Acute lymphoblastic leukemia (ALL) is the commonest malignancy in childhood. While most patients with ALL present with pallor or bleeding signs, some present with localized or diffuse bone pains and t...
|
Nicolien van der Have,
Shriram Vaidia Nath,
Colin Story,
Heather Tapp,
C. Nicola,
Sarah Moore,
Rosemary Sutton,
Tamas Revesz
et al.
|
Short communication
(In Press Corrected Proof)
|
30 January 2012 |
|
Cytarabine in relapsed acute myeloid leukemia
DOI: 10.1016/j.leukres.2011.12.001
The majority of adults with acute myeloid leukemia (AML) in remission will experience a relapse of their disease. Dose-escalated cytarabine has been the mainstay in the treatment of adults with relaps...
|
Brandon M. Hardesty,
Larry D. Cripe
|
Editorial
(In Press Corrected Proof)
|
30 January 2012 |
|
The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line
DOI: 10.1016/j.leukres.2011.12.018
Abstract: In this study, we established an imatinib resistant Ph+ acute lymphoblastic leukemia (ALL) cell line SUP-B15/RI in vitro and studied the mechanism of imatinib resistance. Our results showed ...
|
Hongyun Xing,
Xi Yang,
Ting Liu,
Juan Lin,
Xiaoyi Chen,
Yuping Gong
et al.
|
Full-length article
(In Press Corrected Proof)
|
30 January 2012 |
|
Obesity but not overweight increases the incidence and mortality of leukemia in adults: A meta-analysis of prospective cohort studies
DOI: 10.1016/j.leukres.2011.12.020
Abstract: The main objectives of the present meta-analysis of prospective cohort studies were to evaluate the role of obesity on the incidence and mortality of leukemia in adults. Obesity was associat...
|
Jorge J. Castillo,
John L. Reagan,
Randall R. Ingham,
Michael Furman,
Samir Dalia,
Basma Merhi,
Saed Nemr,
Ali Zarrabi,
Joanna Mitri
et al.
|
Full-length article
(In Press Corrected Proof)
|
30 January 2012 |
|
Rare tetraploidy with large 5q deletion in acute myeloid leukemia with myelodysplasia-related changes (AML-MRC)
DOI: 10.1016/j.leukres.2011.12.014
In 2008, the World Health Organization (WHO) revised its classification of hematopoietic neoplasms and new “acute myeloid leukemia with myelodysplasia-related changes (AML-MRC)” was defined as “AML ar...
|
Marie Jarosova,
Radka Nedomova,
Jaromir Hubacek,
Milena Holzerova,
Pavla Mickova,
Beata Katrincsakova,
Zuzana Pikalova,
Tomas Papajik,
Karel Indrak
et al.
|
Correspondence
(In Press Corrected Proof)
|
27 January 2012 |
|
The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP
DOI: 10.1016/j.leukres.2011.12.012
Abstract: Our objective was to evaluate the non-germinal center (GC) profile as a marker for response and survival in DLBCL and to compare the characteristics of patients with GC and non-GC DLBCL trea...
|
Jorge J. Castillo,
Brady E. Beltran,
Moo-Kon Song,
Ivana Ilic,
Sirpa Leppa,
Heidi Nurmi,
Ritsuko Seki,
Silvia Uccella,
Jun-Min Li,
Diana O. Treaba,
Dariusz Stachurski,
James N. Butera
et al.
|
Full-length article
(In Press Corrected Proof)
|
27 January 2012 |
|
A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes
DOI: 10.1016/j.leukres.2011.12.023
Abstract: Twenty-two patients with myelodysplastic syndromes (MDS) were treated with thalidomide plus arsenic trioxide (ATO). Twenty-two MDS patients receiving supportive care were used as controls. T...
|
Wei Wei,
Fan Zhou,
Yizi Zhang,
Lieping Guo,
Haotian Shi,
Jian Hou
et al.
|
Full-length article
(In Press Corrected Proof)
|
27 January 2012 |
|
Isolation of siRNA target by biotinylated siRNA reveals that human CCDC12 promotes early erythroid differentiation
DOI: 10.1016/j.leukres.2011.12.017
Abstract: Erythroid differentiation is a tightly regulated multi-step process that has not been fully elucidated. We previously reported that a siRNA screened from random siRNA library, siRNA clone-67...
|
Cuiqing Fan,
Lin Dong,
Ning Zhu,
Yuan Xiong,
Jiewen Zhang,
Le Wang,
Yan Shen,
Xiaoyin Zhang,
Meihong Chen
et al.
|
Full-length article
(In Press Corrected Proof)
|
24 January 2012 |
|
The minimal residual disease concept coming of age – Now for the direct comparison of methodologies
DOI: 10.1016/j.leukres.2011.12.022
The concept of minimal residual disease (MRD) and its translational and clinical implications is rapidly gaining recognition as one of the novel paradigms in the follow-up of cancer patients . Thus, t...
|
Hans Beier Ommen,
Anne Stidsholt Roug,
Peter Hokland
|
Editorial
(In Press Corrected Proof)
|
20 January 2012 |
|
A comprehensive cytogenetic classification of 1466 Chinese patients with de novo acute lymphoblastic leukemia
DOI: 10.1016/j.leukres.2011.12.016
Abstract: Cytogenetics and molecular cytogenetics of 1466 Chinese patients with de novo acute lymphoblastic leukemia (ALL) were studied. Cytogenetic results were available in 1175 patients. Cross-corr...
|
Xin Li,
Juan Li,
Yanjie Hu,
Wei Xie,
Wen Du,
Wei Liu,
Xiaoqing Li,
Xiangjun Chen,
Hongrui Li,
Junfeng Wang,
Lannan Zhang,
Shiang Huang
et al.
|
Full-length article
(In Press Corrected Proof)
|
20 January 2012 |
|
A rare cryptic and complex rearrangement leading to MLL-MLLT10 gene fusion masked by del(10)(p12) in a child with acute monoblastic leukemia (AML-M5)
DOI: 10.1016/j.leukres.2011.12.009
Acute myeloid leukemia (AML) in young children, defined as those younger than 24 months of age, occurs in 3–5% of all pediatric leukemias. Rearrangements involving the MLL gene, located on the 11q23 r...
|
Amanda Faria de Figueiredo,
Tarsis Paiva Vieira,
Thomas Liehr,
Samarth Bhatt,
Mariana Tavares de Souza,
Renata Binato,
Terezinha de Jesus Marques-Salles,
Edna Carboni,
Raul C. Ribeiro,
Maria Luiza Macedo Silva,
Eliana Abdelhay
et al.
|
Correspondence
(In Press Corrected Proof)
|
19 January 2012 |
|
PDS5A, a novel translocation partner of MLL in acute myeloid leukemia
DOI: 10.1016/j.leukres.2011.12.006
Mixed lineage leukemia (MLL)-rearranged leukemias represent about 10% of all acute lymphoblastic and myeloid leukemia cases. So far, 71 different MLL fusion partner genes have been characterized at th...
|
Natalie Put,
Katrien Van Roosbroeck,
Isabelle Vande Broek,
Lucienne Michaux,
Peter Vandenberghe
et al.
|
Correspondence
(In Press Corrected Proof)
|
10 January 2012 |
|
Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine
DOI: 10.1016/j.leukres.2011.11.024
Abstract: Azacitidine and decitabine are DNA methyltransferase inhibitors used to treat myelodysplastic syndromes and acute myeloid leukemias. To further characterize different mechanisms between thes...
|
Francesca Buchi,
Elena Spinelli,
Erico Masala,
Antonella Gozzini,
Alessandro Sanna,
Alberto Bosi,
Germano Ferrari,
Valeria Santini
et al.
|
Full-length article
(In Press Corrected Proof)
|
10 January 2012 |
|
Hypomethylating therapy and autoimmunity in MDS: An enigmatic relationship
DOI: 10.1016/j.leukres.2011.12.013
MDS pathogenesis is multifactorial and involves a dynamic interplay of genetic, epigenetic and immune mechanisms. The contribution of the latter is supported by the relatively high percentage of MDS p...
|
Ioannis Kotsianidis,
Emmanouil Spanoudakis,
Evangelia Nakou,
Paraskevi Miltiades,
Dimitrios Margaritis,
Costas Tsatalas,
Argyrios Tzouvelekis,
Anastasia Oikonomou
et al.
|
Correspondence
(In Press Corrected Proof)
|
09 January 2012 |
|
Fludarabine and a histone deacetylase inhibitor – Strange bedfellows
DOI: 10.1016/j.leukres.2011.12.005
Alas, the storm is come again! My best way is to creep under his gaberdine; there is no other shelter hereabout: misery acquaints a man with strange bedfellows. I will here shroud till the dregs of th...
|
H. Miles Prince
|
Editorial
(In Press Corrected Proof)
|
09 January 2012 |
|
Elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia
DOI: 10.1016/j.leukres.2011.12.010
Cytarabine (ara-C, [1-β-d-arabinofuranosylcytosine]), enters cells primarily as a false substrate through specialized nucleoside transporter proteins, predominantly hENT1 (the human equilibrative nucl...
|
Francis Giles,
David Rizzieri,
Farhad Ravandi,
Ronan Swords,
Tove Flem Jacobsen,
Susan O’Brien
et al.
|
Correspondence
(In Press Corrected Proof)
|
09 January 2012 |
|
A novel recurrent translocation t(7;17)(q22;p13) and a late-appearing t(2;3)(p13;q26.2) with dysmegakaryopoiesis in acute myeloid leukemia
DOI: 10.1016/j.leukres.2011.12.007
Deletions of the long arm of chromosome 7 are commonly found in a variety of myeloid malignancies including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) . These abnormalities are de...
|
Katsuya Yamamoto,
Atsuo Okamura,
Yumiko Inui,
Kimikazu Yakushijin,
Hiroshi Matsuoka,
Hironobu Minami
et al.
|
Correspondence
(In Press Corrected Proof)
|
09 January 2012 |
|
Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemia
DOI: 10.1016/j.leukres.2011.12.015
Abstract: The spectrum of underlying molecular abnormalities of clinically and biologically heterogeneous chronic lymphocytic leukaemia (CLL) and prolymphocytic leukaemia (PLL) has yet to be identifie...
|
Stephen E. Langabeer,
Fiona Quinn,
David O’Brien,
Anthony M. McElligott,
Johanna Kelly,
Paul V. Browne,
Elisabeth Vandenberghe
et al.
|
Short communication
(In Press Corrected Proof)
|
09 January 2012 |
|
N-terminally truncated WT1 variant (sWT1) is expressed at very low levels in acute myeloid leukemia and advanced phases of chronic myeloid leukemia
DOI: 10.1016/j.leukres.2011.12.008
The Wilms’ tumour gene 1 (WT1) encodes a multifunctional protein important for regulation of cell growth and survival. It plays a role in many physiological developmental processes and also in cancers...
|
Tereza Lopotová,
Sylvie Nádvorníková,
Markéta Žáčková,
Jaroslav Polák,
Jiří Schwarz,
Hana Klamová,
Jana Moravcová
et al.
|
Correspondence
(In Press Corrected Proof)
|
09 January 2012 |
|
RT-PCR diagnosis of recurrent rearrangements in pediatric acute lymphoblastic leukemia in Argentina
DOI: 10.1016/j.leukres.2011.12.003
Abstract: The present study was performed to establish the prevalence of the recurrent fusion transcripts in Argentinean pediatric patients with acute lymphoblastic leukemia (ALL). A total of 380 newl...
|
Cristina N. Alonso,
Marta S. Gallego,
Jorge G. Rossi,
Adriana Medina,
Patricia L. Rubio,
Andrea R. Bernasconi,
Pedro A. Zubizarreta,
María S. Felice
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 January 2012 |
|
Cardamonin exerts potent activity against multiple myeloma through blockade of NF-κB pathway in vitro
DOI: 10.1016/j.leukres.2011.11.014
Abstract: NF-κB plays a major role in the pathology of multiple myeloma. Here, we intended to investigate the regulating effect of cardamonin on NF-κB in myeloma cells. We found for the first time tha...
|
You Qin,
Chun-Yan Sun,
Fu-Rong Lu,
Xiang-Rong Shu,
Di Yang,
Lei Chen,
Xiao-Mei She,
Nicholas Miller Gregg,
Tao Guo,
Yu Hu
et al.
|
Full-length article
(In Press Corrected Proof)
|
06 January 2012 |
|
Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index
DOI: 10.1016/j.leukres.2011.12.011
In 2007, we reported for the first time that nilotinib, when used as second-line treatment in resistant/intolerant chronic myeloid leukaemia (CML) patients, induced hyperglycaemia as a side effect in ...
|
Massimo Breccia,
Giuseppina Loglisci,
Adriano Salaroli,
Alessandra Serrao,
Giuliana Alimena
et al.
|
Correspondence
(In Press Corrected Proof)
|
04 January 2012 |
|
Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML
DOI: 10.1016/j.leukres.2011.12.002
Abstract: In this study, we show that conditioned media (CM) generated from bone marrow (BM)-derived mesenchymal stromal cells lead to BCR-ABL independent STAT3 activation. Activation of STAT3 is impo...
|
Rajesh R. Nair,
Joel H. Tolentino,
Raul F. Argilagos,
Ling Zhang,
Javier Pinilla-Ibarz,
Lori A. Hazlehurst
et al.
|
Full-length article
(In Press Corrected Proof)
|
04 January 2012 |
|
Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL)
DOI: 10.1016/j.leukres.2011.12.004
Abstract: Adult T-cell leukaemia lymphoma (ATLL) is an aggressive T-cell malignancy caused by the human T-lymphotropic virus type-1 (HTLV-1) and is associated with a very poor prognosis. Combination c...
|
M. Mansour Ceesay,
Estella Matutes,
Graham P. Taylor,
Paul Fields,
Jamie Cavenagh,
Sylwia Simpson,
Aloysius Ho,
Stephen Devereux,
Ghulam J. Mufti,
Antonio Pagliuca
et al.
|
Full-length article
(In Press Corrected Proof)
|
03 January 2012 |
|
Azacitidine in a patient with newly diagnosed acute myeloid leukemia and poor risk cytogenetics: Outcomes of prolonged therapy
DOI: 10.1016/j.leukres.2011.11.022
Acute myeloid leukemia (AML) is predominantly a disease of the elderly, with over half of patients aged >60 years at diagnosis . Prognosis in this age group is typically poor, and use of intensive ...
|
Vasiliki Pappa,
Konstantinos Girkas,
Constantina Sambani,
Sotiris Pagageorgiou,
Panagiotis Tsirigiotis,
Kiki Karvounis,
Evangelia Stathopoulou,
Theofanis Economopoulos,
George Dimitriadis,
Ioannis Dervenoulas
et al.
|
Correspondence
(In Press Corrected Proof)
|
28 December 2011 |
|
Prognostic implications of leg ulcers from hydroxycarbamide therapy in patients with essential thrombocythaemia
DOI: 10.1016/j.leukres.2011.11.017
Abstract: Essential thrombocythemia (ET) is a clonal stem-cell disorder characterized by persistent thrombocytosis. Patients with ET and risk factors for thrombotic complications have been shown to be...
|
Sebastian Francis,
David Bareford,
Christina Baginott,
Jecko Thachil
|
Short communication
(In Press Corrected Proof)
|
26 December 2011 |
|
The activity of the inosine triphosphate pyrophosphatase affects toxicity of 6-mercaptopurine during maintenance therapy for acute lymphoblastic leukemia in Japanese children
DOI: 10.1016/j.leukres.2011.11.015
Abstract: The association between inosine triphosphate pyrophosphatase (ITPA) activity and toxicity of 6-mercaptopurine (6-MP) was retrospectively evaluated in 65 Japanese children with acute lymphobl...
|
Yoichi Tanaka,
Atsushi Manabe,
Hisaya Nakadate,
Kensuke Kondoh,
Kozue Nakamura,
Katsuyoshi Koh,
Tomoyuki Utano,
Akira Kikuchi,
Takako Komiyama
et al.
|
Full-length article
(In Press Corrected Proof)
|
26 December 2011 |
|
Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets
DOI: 10.1016/j.leukres.2011.11.020
Abstract: Despite a high remission rate, a significant number of patients with acute myeloid leukemia (AML) relapse. Thus, the evaluation of minimal residual disease (MRD) in AML is an important strat...
|
Giovanni Rossi,
Maria Marta Minervini,
Angelo Michele Carella,
Chiara de Waure,
Francesco di Nardo,
Lorella Melillo,
Giovanni D’Arena,
Gina Zini,
Nicola Cascavilla
et al.
|
Full-length article
(In Press Corrected Proof)
|
26 December 2011 |
|
The hematopoietic cell transplantation comorbidity index is a predictor of early death and survival in adult acute myeloid leukemia patients
DOI: 10.1016/j.leukres.2011.11.021
Abstract: The hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of early death and survival in elderly patients with acute myeloid leukemia (AML). The aim of this study was t...
|
Aleksandar Savic,
Vanja Kvrgic,
Nebojsa Rajic,
Ivana Urosevic,
Dragan Kovacevic,
Ivanka Percic,
Stevan Popovic
et al.
|
Short communication
(In Press Corrected Proof)
|
22 December 2011 |
|
Long-term transfusion independence in del(5q) MDS patients after short term therapy with lenalidomide: 2 new cases
DOI: 10.1016/j.leukres.2011.11.023
The introduction of the immunomodulatory drug lenalidomide has revolutionized the treatment of patients with myelodysplastic syndromes and interstitial deletion of the long arm of chromosome 5 [del5(q...
|
Andreas Himmelmann,
Joëlle Tchinda
|
Correspondence
(In Press Corrected Proof)
|
19 December 2011 |
|
Immune-mediated peripheral neuropathy occurring simultaneously with recurrent graft-versus-host disease after allogenic hematopoietic stem cell transplantation
DOI: 10.1016/j.leukres.2011.11.025
Peripheral neuropathy is a rare but important complication of allogenic hematopoietic stem cell transplantation (allo-HSCT). Although it is potentially curable, it sometimes has a tremendous impact on...
|
Yukiko Doi,
Hiroyuki Sugahara,
Kazutaka Yamamoto,
Hidetoshi Uji-ie,
Tsunayuki Kakimoto,
Hiroto Sakoda
et al.
|
Correspondence
(In Press Corrected Proof)
|
19 December 2011 |
|
Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms
DOI: 10.1016/j.leukres.2011.11.018
Abstract: Somatic mutations of the two genes coding for the histone acetyltransferase genes, CREEBP and EP300 have been identified as a pathogenetic mechanism shared by common forms of B-cell non-Hodg...
|
Christen Lykkegaard Andersen,
Hans Hasselbalch,
Kirsten Grønbæk
|
Short communication
(In Press Corrected Proof)
|
19 December 2011 |
|
Tumor necrosis factor alpha−308 and Lymphotoxin alpha+252 genetic polymorphisms and the susceptibility to non-Hodgkin lymphoma in Egypt
DOI: 10.1016/j.leukres.2011.11.016
Abstract: Genetic polymorphism within the regulatory regions of tumor necrosis factor-alpha (TNF-α) and Lymphotoxin-alpha (LT-α) may be involved in the development of lymphoid malignancies. The aim of...
|
Azza Ibrahim,
Hala Abdel Rahman,
Mervat Khorshied,
Rania Sami,
Nelly Nasr,
Ola Khorshid
et al.
|
Full-length article
(In Press Corrected Proof)
|
19 December 2011 |
|
Glycogen synthase kinase-3 (GSK-3) inhibition induces apoptosis in leukemic cells through mitochondria-dependent pathway
DOI: 10.1016/j.leukres.2011.11.013
Abstract: The roles of glycogen synthase kinase-3 (GSK-3) in cell survival and apoptosis are controversial. We examined the effect of a specific GSK-3 inhibitor (SB-415286) on the regulation of leukem...
|
Mohammad Reza Mirlashari,
Ingrid Randen,
Jens Kjeldsen-Kragh
|
Full-length article
(In Press Corrected Proof)
|
19 December 2011 |
|
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
DOI: 10.1016/j.leukres.2011.11.019
Abstract: We studied a retrospective cohort of 282 higher-risk MDS treated with azacitidine, including 32 patients who concomitantly received an ESA for a median of 5.8months after azacitidine onset. ...
|
R. Itzykson,
S. Thépot,
O. Beyne-Rauzy,
S. Ame,
F. Isnard,
F. Dreyfus,
C. Salanoubat,
A.L. Taksin,
Y. Chelgoum,
C. Berthon,
J.V. Malfuson,
L. Legros,
N. Vey,
P. Turlure,
C. Gardin,
S. Boehrer,
L. Ades,
P. Fenaux,
on behalf of the Groupe Francophone des Myelodysplasies (GFM)
et al.
|
Full-length article
(In Press Corrected Proof)
|
19 December 2011 |
|
Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia
DOI: 10.1016/j.leukres.2011.10.027
Abstract: Mitoxantrone and etoposide (ME) salvage regimens have been successfully used for the treatment of primary induction failure or relapsed acute myeloid leukemia (AML). Whether the addition of ...
|
Steven M. Trifilio,
Alfred W. Rademaker,
Diane Newman,
Katherine Coyle,
Katrin Carlson-Leuer,
Jayesh Mehta,
Jessica Altman,
Olga Frankfurt,
Martin S. Tallman
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 December 2011 |
|
Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study
DOI: 10.1016/j.leukres.2011.11.011
Abstract: Lenalidomide is known to be effective in myelodysplastic syndromes (MDS) with del(5q) in improving anemia and suppressing del(5q) cells. MDS with del(5q) shows increase of nonlobulated megak...
|
Akira Matsuda,
Masafumi Taniwaki,
Itsuro Jinnai,
Hironori Harada,
Mitsumasa Watanabe,
Kenshi Suzuki,
Soshi Yanagita,
Takahiro Suzuki,
Yataro Yoshida,
Akiro Kimura,
Mitsuru Tsudo,
Kaoru Tohyama,
Masaaki Takatoku,
Keiya Ozawa
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 December 2011 |
|
The impact of the dose of natural killer cells in the graft on severe acute graft-versus-host disease after unrelated bone marrow transplantation
DOI: 10.1016/j.leukres.2011.11.009
Abstract: The impact of lymphocyte subpopulations on the outcome of bone marrow transplantation (BMT) remains uncertain. We investigated the relationship between the lymphocyte subpopulations of bone ...
|
Masatsugu Tanaka,
Shoichi Kobayashi,
Ayumi Numata,
Takayoshi Tachibana,
Hirotaka Takasaki,
Atsuo Maruta,
Yoshiaki Ishigatsubo,
Heiwa Kanamori
et al.
|
Full-length article
(In Press Corrected Proof)
|
15 December 2011 |
|
Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia
DOI: 10.1016/j.leukres.2011.10.023
Abstract: Sodium salicylate is an inexpensive, readily available anti-inflammatory agent which inhibits NF-κB in in vitro models. We examined whether it was possible to safely achieve and maintain sal...
|
Virginia M. Klimek,
Emily K. Dolezal,
Larry Smith,
Gerald Soff,
Stephen D. Nimer
et al.
|
Full-length article
(In Press Corrected Proof)
|
12 December 2011 |